Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

BACKGROUND: Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). METHODS: The efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wei, Yang, Shenmiao, Zhou, Keshu, Pan, Ling, Li, Zengjun, Zhou, Jianfeng, Gao, Sujun, Zhou, Daobin, Hu, Jianda, Feng, Ru, Huang, Haiwen, Ji, Meng, Guo, Haiyi, Huang, Jane, Novotny, William, Feng, Shibao, Li, Jianyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216400/
https://www.ncbi.nlm.nih.gov/pubmed/32393328
http://dx.doi.org/10.1186/s13045-020-00884-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216400/
https://www.ncbi.nlm.nih.gov/pubmed/32393328
http://dx.doi.org/10.1186/s13045-020-00884-4

Ejemplares similares